Ranolazine: its role in the medical treatment of stable angina
There have been significant advances in the management of coronary artery disease (CHD) in recent years; including in medical therapy, revascularisation, secondary prevention, cardiac rehabilitation and lifestyle interventions, which have resulted in improved prognosis and life expectancy. As a consequence, an increasing number of patients are living longer with CHD, the commonest clinical presentation of which is angina pectoris. In patients with stable angina, the focus of treatment has therefore shifted towards ensuring optimal symptom control and improving quality of life. Ranolazine is an antianginal approved for patients with stable angina, whose symptoms are inadequately controlled by - or they are intolerant of - first-line therapy.